Basel, 09 September 2013
Genentech Executive Vice President wins Lasker Award
Richard Scheller Recognized for Seminal Advances in Neuroscience
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Richard Scheller, Ph.D., Executive Vice President, Head of Genentech Research and Early Development, is a winner of the 2013 Albert Lasker Basic Medical Research Award, given annually to a scientist whose fundamental investigations have provided techniques, information or concepts contributing to the elimination of major causes of disability and death.
The Lasker Awards are among the most renowned science prizes in the world and have become popularly known as “America’s Nobels." Dr. Scheller shares this year’s award with Thomas Südhof, Professor of Molecular and Cellular Physiology at Stanford University, for their discoveries concerning rapid neurotransmitter release, a process that underlies all of the brain’s activities. Dr. Scheller is donating his proceeds from the award to the Wildlife Conservation Network, a San Francisco Bay Area-based organization dedicated to protecting endangered species and preserving their natural habitats.
Dr. Scheller is a member of Genentech's executive committee and the Enlarged Roche Corporate Executive Committee. He is responsible for overseeing the strategy for Genentech's research, drug discovery, business development and early development activities. Prior to joining Genentech in 2001, Dr. Scheller was Professor of Molecular and Cellular Physiology and Biological Science at Stanford University and an investigator with the Howard Hughes Medical Institute.
Dr. Scheller has published more than 200 papers in peer-reviewed scientific journals. He is a member of the Academy of Arts and Sciences and the National Academy of Sciences, and the recipient of numerous scientific awards including the 2010 Kavli Prize in Neuroscience. Scheller received his Bachelor of Science in biochemistry at the University of Wisconsin, Madison, where he received the Distinguished Alumni Award in 2009. He was awarded his doctorate in chemistry from the California Institute of Technology. He was a postdoctoral fellow at both the California Institute of Technology and Columbia University.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.